Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 12/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12539724 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NPSR1TRPV1MTNR1AMTNR1B | |
| SCHEMBL14544486 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL13794162 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL1197466 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL862934 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL25021708 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL1600902 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| Hydrochloric Acid SCHEMBL28254537 | 0.85 | SMN1; SMN2 (0.96) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL294182 | 0.75 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A | |
| SCHEMBL12269958 | 0.75 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1MTNR1AMTNR1BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802711-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2688866-A1 | TRPV1 ANTAGONISTS | AbbVie Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012134943-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120245163-A1 | TRPV1 Antagonists | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245163-A1 | TRPV1 Antagonists | TRPV1, TRPV3, TRPV6 | SMN1; SMN2 2907/4885NPSR1 153/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.